SOPHiA GENETICS (NASDAQ:SOPH) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research note released on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $6.00 target price on the stock.

Several other equities analysts also recently weighed in on the stock. BTIG Research raised their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a buy rating in a research note on Wednesday, March 6th. Royal Bank of Canada reissued an outperform rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Wednesday, March 6th.

SOPHiA GENETICS Trading Down 1.3 %

SOPH stock opened at $4.58 on Thursday. The business’s 50-day moving average is $4.85 and its 200 day moving average is $4.82. SOPHiA GENETICS has a 12-month low of $2.13 and a 12-month high of $7.37. The stock has a market cap of $299.44 million, a price-to-earnings ratio of -4.09 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. The firm had revenue of $15.78 million during the quarter, compared to analysts’ expectations of $16.80 million. SOPHiA GENETICS had a negative return on equity of 47.56% and a negative net margin of 113.71%. As a group, equities analysts forecast that SOPHiA GENETICS will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of SOPHiA GENETICS by 90.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock worth $65,000 after buying an additional 6,552 shares during the last quarter. Legato Capital Management LLC purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at $235,000. Essex Investment Management Co. LLC acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $584,000. Federated Hermes Inc. grew its holdings in shares of SOPHiA GENETICS by 100.0% during the 3rd quarter. Federated Hermes Inc. now owns 160,000 shares of the company’s stock worth $408,000 after purchasing an additional 80,000 shares during the period. Finally, Moloney Securities Asset Management LLC increased its position in shares of SOPHiA GENETICS by 111.4% during the 1st quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock worth $878,000 after purchasing an additional 93,800 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.